---
schema_version: "secwatch.filing_event.v1"
accession: "0001599298-26-000004"
form_type: "8-K"
ticker: "SMMT"
cik: "0001599298"
company_name: "Summit Therapeutics Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:52:30.737870+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Summit submits BLA for ivonescimab in EGFRm NSCLC; $710M cash; GSK collaboration

## Summary
- BLA submitted to FDA for ivonescimab + chemo in 2L+ EGFR-mutated NSCLC based on Phase III HARMONi; FDA decision expected Q4 2026.
- Preliminary cash, cash equivalents, and short-term investments of ~$710M as of Dec 31, 2025.
- Clinical collaboration with GSK to evaluate ivonescimab + risvutatug rezetecan (B7-H3 ADC) across solid tumors; dosing expected mid-2026.
- Over 14,000 patients in the US annually eligible for 2L+ treatment of EGFRm NSCLC.

## SEC filing metadata
- accession: 0001599298-26-000004
- form_type: 8-K
- ticker: SMMT
- cik: 0001599298
- company_name: Summit Therapeutics Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1599298/000159929826000004/0001599298-26-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1599298/000159929826000004/smmt-20260112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001599298-26-000004
- JSON: https://secwatch.observer/filing/0001599298-26-000004.json
- Plain text: https://secwatch.observer/filing/0001599298-26-000004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.